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Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression, but sexual side effects often compromise
compliance. These reproductive dysfunctions are likelymediated by elevations of the hormone prolactin. Yet, how serotonin (5-HT) and
SSRIs cause changes in prolactin secretion is not known. Here, using in vitro whole-cell patch-clamp recordings, we show that 5-HT
hyperpolarizes and abolishes phasic discharge in rat neuroendocrine tuberoinfundibular dopamine (TIDA) neurons, themain inhibitor
of prolactin secretion. This process is underpinned by 5-HT1A receptor-mediated activation of G-protein-coupled inwardly rectifying
K-like currents. We further demonstrate that the SSRIs, fluoxetine and sertraline, directly suppress TIDA neuron activity through
parallel effects, independent of 5-HT transmission. This inhibition involves decreased intrinsic excitability and a slowing of TIDA
network rhythms. These findings indicate that SSRIs may inhibit neuroendocrine dopamine release through both 5-HT-dependent
and -independent actions, providing a mechanistic explanation for, and potential molecular targets for the amelioration of, the hyper-
prolactinemia and sexual dysfunction associated with these drugs.
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Introduction
Selective serotonin reuptake inhibitors (SSRIs) were originally
developed for the treatment ofmooddisorders but have also been
approved to treat a widening spectrum of conditions, including
anxiety, obsessive compulsive disorder, and bulimia nervosa. De-
pressive disorders, with a global prevalence exceeding 4% (Vos et
al., 2012), are projected to be the leading cause of disease burden
by 2030 (World Health Organisation, 2008). SSRIs are recom-
mended as a front-line therapy formoderate to severe depression
(American Psychiatric Association, 2000), and population prev-
alence of SSRI use as high as 3.5% has been described (Olie´ et al.,
2002). Unfortunately, SSRI compliance is compromised by the
high incidence of adverse effects. Sexual side effects, including
amenorrhea, infertility, anorgasmia, impotence, and impaired
libido, are often under-reported (Montejo-Gonza´lez et al., 1997)
but, when systematically assessed, are experienced by40%of all
SSRI users (Clayton et al., 2002), often leading to cessation of
treatment (van Geffen et al., 2007).
The adverse sexual effects associated with SSRIs are com-
monly attributed to elevation of the pituitary hormone, prolactin
(Safarinejad, 2008;Madhusoodanan et al., 2010). Prolactin exerts
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Significance Statement
Depression affects approximately one-tenth of the population and is commonly treated with selective serotonin reuptake inhib-
itors (SSRIs; e.g., Prozac). Yet, many patients withdraw from SSRI therapy due to sexual side effects (e.g., infertility, menstrual
disturbances, and impotence). Although it is generally accepted that sexual side effects are due to the ability of these drugs to
elevate blood levels of the hormoneprolactin, themechanism for this hormonal imbalance is not known.Here,we show that SSRIs
can inhibit hypothalamic dopamine neurons that normally suppress the secretion of prolactin. Intriguingly this inhibition can be
explained both by increased serotonin activity and also by parallel serotonin-independent actions.
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a range of physiological effects that decrease fertility and libido
(Bole-Feysot et al., 1998), and hyperprolactinemia, caused, for
example, by pituitary adenomas or induced iatrogenically, results
in reproductive dysfunction, such as menstrual disturbances and
impotence (e.g., Schlechte et al., 1980; Buvat et al., 1985). Hyper-
prolactinemia is commonwith SSRIs, such as fluoxetine (Prozac)
and sertraline (Urban and Veldhuis, 1991; Ekselius et al., 1997;
Gregorian et al., 2002; Petit et al., 2003), and was originally de-
scribed in animal studies (e.g., Morgan and Herbert, 1978). Im-
portantly, serotonin (5-HT) itself was first shown to be a potent
prolactin-releasing agent 4 decades ago (Kamberi et al., 1971;
Lu and Meites, 1973).
It is not well understood how 5-HT and SSRIs promote pro-
lactin release (Emiliano and Fudge, 2004). Direct stimulation of
prolactin-producing lactotrophs is unlikely because administra-
tion of 5-HT to isolated pituitary preparations does not promote
prolactin secretion (Birge et al., 1970). The release of prolactin is,
however, under powerful control by neuroendocrine tuberoin-
fundibular dopamine (TIDA) neurons located in the hypotha-
lamic arcuate nucleus (Lyons and Broberger, 2014). Dopamine
released from TIDA neurons reaches the pituitary through the
portal capillary system and tonically suppresses prolactin release
via inhibitory dopamineD2-type receptors. Recentwork suggests
that neuromodulators and hormones that influence prolactin re-
lease and lactation may do this by altering the passive and active
membrane properties of TIDA neurons (Lyons et al., 2010, 2012;
Briffaud et al., 2015; Zhang and van den Pol, 2015) Here, we have
investigated whether 5-HT and three SSRIs (fluoxetine, sertra-
line, and fenfluramine) can alter the electrophysiology of TIDA
cells in a way that may explain the prolactin-releasing actions of
these compounds.
Materials andMethods
Animals
Male Sprague Dawley rats (Charles River), 22- to 30-d-old for electro-
physiology experiments and 4- to 6-weeks-old for immunofluorescence,
were housed with free access to standard chow and tap water in a
temperature-controlled environment under 12 h/12 h light/dark condi-
tions. All animal experiments had received prior approval by the local
ethical board, Stockholms Norra Djurfo¨rso¨ksetiska Na¨mnd, and were
performed in accordance with the European Communities Council Di-
rective of November 24, 1986 (86/609/EEC).
Electrophysiology
Electrophysiological experiments were performed as previously de-
scribed (Lyons et al., 2012). Rats (n 83) were anesthetized with sodium
pentobarbital and decapitated. The brain was removed and placed in
cold, oxygenated (95%O2/5%CO2) “slicing” solution containing the fol-
lowing (in mM): 214 sucrose, 2.0 KCl, 1.2 NaH2PO4, 26 NaHCO3, 1.3
MgSO4, 2.4 CaCl2, and 10 D-glucose. The brain was glued to a vibratome
(Leica), and 250m thick coronal sections of the hypothalamus, includ-
ing the arcuate nucleus, were prepared. Slices were immediately trans-
ferred to a “recording” solution containing the following (in mM): 127
NaCl, 2.0 KCl, 1.2 NaH2PO4, 26 NaHCO3, 1.3 MgCl2, 2.4 CaCl2, and 10
D-glucose, in a continuously oxygenated holding chamber at 35°C for a
period of 25min. Subsequently, sliceswere allowed to recover in “record-
ing” solution at room temperature for a minimum of 1 h before record-
ing. For whole-cell recordings, slices were transferred to a submerged
chamber and placed on an elevated grid that allows perfusion both above
and below the slice. An Axioskop 2 FS Plus upright microscope (Carl
Zeiss) was used for infrared-differential interference contrast visualiza-
tion of cells. Recordings were performed at room temperature (22°C),
and slices were continuously perfused with oxygenated “recording” so-
lution (as above) unless otherwise described at a rate of5 ml/min. All
pharmacological compounds were bath applied.
Whole-cell current- and voltage-clamp recordings were performed
with pipettes (3–7 Mwhen filled with intracellular solution)made from
borosilicate glass capillaries (World Precision Instruments) pulled on a
P-97 Flaming/Brown micropipette puller (Sutter Instruments). The in-
tracellular recording solution contained (in mM) the following: 140
K-gluconate, 10KCl, 10HEPES, 1 EGTA, 2Na2ATP, pH7.3 (withKOH).
When investigating IPSCs, a High Cl intracellular solution was used
comprised of the following (in mM): 150 KCl, 10 HEPES, 1 EGTA, 2
Na2ATP), pH 7.3 (with KOH). The concentration used for TTX was 500
nM. In experiments that required the raising of K conductances, rever-
sal potential high K extracellular recording solution containing the
following (in mM): 127 NaCl, 10 KCl, 1.2 NaH2PO4, 26 NaHCO3, 1.3
MgCl2, 2.4 CaCl2, 10 D-glucose was used. Recordings were performed
using a Multiclamp 700B amplifier and pClamp9 software (Molecular
Devices). Access resistance was monitored throughout the experiments,
and neurons in which the series resistance was 25 M or changed
15% were excluded from the statistics. Liquid junction potential was
16.4 mV and not compensated. The recorded current was sampled at 10
kHz and filtered at 2 kHz unless otherwise stated. In voltage-clamp ex-
periments, the holding potential was60 mV unless otherwise stated.
To determine the 5-HT-induced current in the presence of TTX fre-
quency distribution, histograms were plotted for 10 s of control, 5-HT,
and wash traces with Gaussian fits performed on the individual and
pooled distributions. The mean difference between the Gaussian peaks
for control and 5-HT was used as the value for 5-HT-induced current.
The spectral density plot of the underlying oscillation was produced by
filtering the trace with a 1 Hz low pass filter and performing spectral
analysis with a rectangular window function on 56.5 s segments giving a
spectral resolution of 0.019 Hz. To quantify GABAergic synaptic events,
100 s segments in control and during response were selected for analysis
and comparison.
Immunofluorescence
Rats (n  4) were perfused with a fixative of 5% glutaraldehyde/1%
sodium bisulfite in cacodylate buffer; 14-m-thick coronal brain sections
were processed for indirect immunofluorescence as previously described
usingmousemonoclonal anti-TH antibodies (1:2000;Millipore) and rabbit
anti-serotonin (5-HT) antiserum (1:250; Millipore) (Foo et al., 2014).
Statistical analysis and reagents
Data analysis was performed with OriginPro8.5 (OriginLab), Clamp-
fit 9 (Molecular Devices), and Mini Analysis 6.0.9 (Synaptosoft) soft-
ware. Statistical significance was set at p  0.05. All reagents were
purchased from Sigma Pharmaceuticals, with the exception of TTX,
which was purchased from Alomone Labs, and 8-hydroxy PIPAT
oxalate (	)-8-hydroxy-2-dipropylaminotetralin hydrobromide (8-
OH-DPAT), NAD299 hydrochloride, fluoxetine hydrochloride, ser-
traline hydrochloride, and dexfenfluramine hydrochloride, which
were purchased from Tocris Bioscience.
Results
5-HT directly inhibits oscillating TIDA neurons
TIDAneurons display a synchronized network oscillation (Lyons
et al., 2010, 2012), characterized by alternating periods of hyper-
polarization and depolarization (Fig. 1A). This stereotyped oscil-
lation provides a reliable electrical signature for rat TIDA
neurons in vitro (Lyons et al., 2010, 2012). When 5-HT (10 M)
was applied to TIDA neurons (in current-clampmode), a revers-
ible hyperpolarization and cessation of both oscillation and pha-
sic discharge were consistently observed (n  27 of 27; 100%;
Fig. 1A,B).
Immunohistochemical staining for 5-HT and TH (the rate-
limiting enzyme in catecholamine biosynthesis) revealed 5-HT-
immunoreactive fibers in close apposition to TIDA somata and
dendrites, thus providing an anatomical substrate for the direct
5-HT-ergic modulation of TIDA activity (Fig. 1C). This was con-
firmed pharmacologically, as in the presence of the Na channel
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blocker TTX (500 nM), which also abolishes the TIDA oscillation
(Lyons et al., 2010, 2012), 5-HT (10 M) induced a rapid and
reversible 22.9 	 1.6 mV hyperpolarization (n  5; p  0.005;
ANOVA; F(2,12)  163.4; Fig. 2A,B) (this value was used as a
control 5-HT response for current-clamp tests where paired
comparisons were not possible), and a 9.7 	 2.1% reduction in
input resistance (n  5; p  0.01; ANOVA; F(2,12)  10.7; Fig.
2A,B). A second application of 5-HT resulted in a 19.3	 2.0mV
Figure 1. Serotonin inhibits TIDA neurons. A, Current-clamp, oscillating rat TIDA neuron. 5-HT (10M) application results in hyperpolarization and abolishment of phasic discharge. Calibration:
20mV, 30 s. Bottom, Expanded sections highlighted inAwith the color-coordinated 1 Hz filter superimposed and the corresponding spectral analysis opposite. Calibration: 20mV, 2 s.B, Frequency
spectrogram of the entire trace depicted in A. There is reversible abolishment of TIDA oscillation power by 5-HT. C, Confocal micrographs from rat hypothalamus stained by immunofluorescence for
TH (red) and 5-HT (green). Boxed area enlarged in Inset. 5-HT-immunoreactive terminals form close appositions on somata (filled arrows) and dendrites (open arrows) of TH-expressing TIDA
neurons. Scale bars: 100m; Inset, 10m. 3V, Third ventricle; ARC, arcuate nucleus.
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(n  5; p  0.01; ANOVA; F(2,12)  21.8) hyperpolarization
(88.0	 3.6% of the initial response; n 5; Fig. 2C) indicative of
small, yet significant, tachyphylaxis. The 5-HT response also
demonstrated a degree of dose dependence, with 1 M 5-HT
inducing a significant 5.3 	 1.2 mV (n  5, p  0.01; t test
paired; t 4.4) hyperpolarization, whereas 250 nM failed to elicit
a response (0.8	 .1.1; n 5; not significant; t test paired; t
0.7; data not shown). These results demonstrate that 5-HT inhib-
its TIDA neurons via a direct, postsynaptic mechanism.
5-HT activates a G-protein-coupled inwardly rectifying
potassium (GIRK)-like current
The ionic mechanisms underlying the 5-HT-induced hyperpo-
larization were investigated in voltage clamp. In the presence of
TTX, application of 5-HT (10 M) resulted in a reversible out-
ward current of 17.3 	 2.2 pA (n  10; p  0.005; ANOVA;
F(2,27)  52.4; Fig. 3A) (this value was used as a control 5-HT
response for voltage-clamp tests where paired comparisons were
not possible, “Control I5-HT”). Digital subtraction of voltage-
clamp ramps performed in control from those at the peak of
response revealed the 5-HT-induced current (I5-HT) to be a net
outward current (Fig. 3Ai) with an estimated reversal potential of
128.1 mV (Fig. 3Aii), lower than that calculated for K
(110.6 mV).
As this reversal potential was lower than that predicted for
K, possibly due to the role of gap junctions in the TIDA oscil-
lation (Lyons et al., 2010) and their potential impact on space
clamp, we sought to further investigate the role of K currents in
the generation of I5-HT. Potassium channels were blocked
through a Cs-based internal solution. Here, 5-HT (10 M) ap-
plication induced only a 5.8	 0.7 pA outward current (n 10;
p 0.005; t test paired; t8.9; Fig. 3B,Bi), a significant 66.5	
3.8% reduction of the control 5-HT response (n 10; p 0.005
vs control I5-HT; t test unpaired; t 5.1; Fig. 3A,Bii).
Next, [K]o was raised to 10 mM, shifting the calculated K

reversal potential to 68 mV. At our holding potential of 60
mV, application of 5-HT (10 M) failed to induce an outward
current (1.0 	 0.6 pA; n  10; not significant; t test paired; t 
1.7; Fig. 3C), with I5-HT exhibiting a reversal potential of 58.9
mV and mild inward rectification (Fig. 3Ci).
Neuronal hyperpolarization by 5-HThas been associatedwith
activation of GIRK channels (Penington et al., 1993; Lu¨scher et
al., 1997). To investigate the potential role of GIRK channels, we
sequentially applied 5-HT to TIDA neurons in the absence and
presence of Ba2 (300 M), a nonspecific blocker of inwardly
rectifying K channels. In the presence of Ba2, 5-HT induced a
6.7	 1.5 pA outward current (n 5; p 0.05; t test paired; t
4.4; Fig. 3D), a significant 75.1 	 6.5% reduction compared
with the initial, 29.0	 2.5 pA (n 5), response to 5-HT (n 5;
p 0.005; ANOVA; F(2,12) 35.3; Fig. 3Di). This reduction was
not due to desensitization as following washout of 5-HT and
Ba2, reapplication of 5-HT induced an outward current of
26.4	 2.4 pA (n 5; p 0.005; t test paired; t11.1), which
proved indistinguishable from the first response (n 5; not sig-
nificant; ANOVA; F(2,12) 35.3; Fig. 3D,Di). The selective GIRK
channel blocker Tertiapin Q (TQ), a derivative of the honey bee
venom tertiapin (Jin and Lu, 1999), was also tested. The applica-
tion of 5-HT in the presence of TQ (300 nM) induced a 9.5	 2.2
Figure 2. Serotonin inhibits TIDA neurons via a postsynaptic mechanism. A, Current-clamp trace, oscillating TIDA neuron. The 5-HT (10M)-induced hyperpolarization endures in the presence
of TTX (500nM). Initialmembranepotentialwas set at
65mV, a value achievedwith the injectionof negativeDC current. Input resistancewas assessedby square-formnegative current injection
(asterisks). For purposes of comparison at peak of response,membrane potential was returned to65mVwith additional DC current (arrow). Inset, Superimposedmembrane potential deflections
in control (green) and5-HT (red). Calibration: 10mV, 20 s; Inset, 20mV, 250ms.B, Summary of 5-HT-inducedeffects onmembranepotential (green) and input resistance (red) recordedas inA. Thick
lines indicate mean	 SEM. Dashed lines indicate raw data (n 5). C, Desensitization of the 5-HT response recorded as in A following repeated applications (after 15 min of wash). Thick lines
indicate mean	 SEM. Dashed lines indicate raw data (n 5). *p 0.05. **p 0.01. ***p 0.005. ns, Not significant.
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pA outward current (n 5; p 0.01, t test paired; t4.4 Fig.
3Dii), a significant 48.5 	 6.4% reduction compared with the
initial, 18	 3.1 pA (n 5), response to 5-HT (n 5; p 0.005,
t test paired; t  4.8; Fig. 3Dii). Furthermore, preincubation of
slices (15–20 min) with the G-protein blocker N-ethylmaleimide
(NEM; 250 M) resulted in an 81.9% diminution of the 5-HT
control response (3.0	 1.0 pA; n 5; p 0.005 vs control I5-HT;
t test unpaired; t 4.5; Fig. 3A,Dii).
Collectively these results indicate that I5-HT in TIDA neurons
likely involves activation of GIRK-like channels.
5-HT inhibits TIDA neurons via the 5-HT1A receptor
In vivo studies have implicated 5-HT1A (Mulroney et al., 1994;
Jørgensen et al., 2001), 5-HT2A (Liang and Pan, 2000), and
5-HT2C (Jørgensen et al., 1992) receptors in 5-HT’s modulation
of prolactin secretion. The broad-spectrum 5-HT2 receptor an-
tagonist methiothepin (5 M) failed to block the 5-HT-induced
hyperpolarization of TIDA neurons (Control 5-HT23.6	 1.8
mV vs methiothepin 5-HT 19.8 	 2.4 mV; n  3; not signifi-
cant; t test paired; t  2.4; data not shown). In contrast, the
selective 5-HT1A antagonist, NAD 299 (1 M) completely
Figure3. Serotonin activates GIRK-like channels.A, Voltage-clamp, oscillating TIDA neuron recorded in the presence of TTX. Application of 5-HT results in an outward current. Right, Gaussian fits
of averaged (solid lines) holding current frequency distributions in control (green), 5-HT (red), and wash (black) (n 10), sharing its y-axis with the raw trace. Dashed lines indicate raw data used
to produce averages. Calibration: 5 s. Ai, Averaged 5-HT induced current	 SEM obtained by the digital subtraction of voltage-clamp ramps in control and at peak of 5-HT response (n 10). Aii,
Linear extrapolation of the 5-HT-induced current indicated by the box inAi. There is projected reversal potential (Erev) of128.1mV.B, Voltage-clamp, oscillating TIDAneuron recorded as in Figure
3A, and with Cs-based intracellular solution used to block K-currents. Application of 5-HT induces a substantially reduced outward current (compare A). Right, Gaussian fits of holding current
frequency distributions in control (green) and 5-HT (red). (n 10). Calibration: 10 s. Bi, Averaged current-voltage relationship	 SEM of I5-HT in control (green, n 10) and with Cs
-based
intracellular solution (red, n 10), obtained as in Ai. There is reduction of I5-HT when Cs
-based intracellular solution is used. Bii, Box plot of I5-HT recorded in voltage clamp with Cs
-based or
control intracellular solution. Boxes represent 25th, 50th, and75thpercentilewith superimposedmean	SEMandmaximumandminimumvalues (controln10, Csn10).C, Voltage-clamp,
oscillating TIDA neuron recorded as in A in the presence of high extracellular K. Application of 5-HT fails to induce a significant current (n 10). Calibration 5 s. Ci, Averaged current-voltage
relationship	 SEM of I5-HT in the presence of High extracellular K
 (n 10), obtained as shown in Ai. There is a shift of the reversal potential and presence of inward rectification (compared Ai).
Cii, High [K] O significantly reduces I5-HT. Box plot organized as Bii (control n 10, High [K
] O n 10). D, Voltage-clamp trace, oscillating TIDA neuron recorded as in A (there is abolishment
of oscillation in response to TTX). 5-HT is applied before, during, and after Ba is present in the bath. There is Ba-induced reduction of I5-HT. Calibration: 10 pA, 60 s. Di, Ba
 significantly and
reversibly reduces I5-HT. Box plot organized asBii (n 5).Dii, TQ (n 5) and the G-protein inhibitor NEM (control n 10, NEM n 5) significantly reduces I5-HT. Box plot organized asBii. ***p
0.005. ns, Not significant.
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blocked the 5-HT-induced effect (0.3 	 0.7 pA; n  12; not
significant; t test paired; t0.4; Fig. 4A), a response statistically
different from initial response to 5-HT (20.9 	 5.2 pA; n  12;
p  0.005; ANOVA; F(2,33)  25.6; Fig. 4Ai). Incubation with
NAD 299 alone did not alter baseline current (Control15.1	
4.1 pA vs NAD29915.0	 4.2 pA; n 12; not significant; t test
paired; t0.17; data not shown).
The 5-HT1A-selective agonists, 8-OH-PIPAT and 8-OH-
DPAT, were also tested. Application of 8-OH-DPAT induced a
20.4	 2.0 pA (n 10; p 0.005; t test paired; t10.2; Fig. 4B)
outward current, corresponding to 90.2 	 3.7% of the initial
response to 5-HT (22.8 	 2.4 pA; n  10; not significant; t test;
t 1.9; paired; Fig. 4Bi). 8-OH-PIPAT also induced an outward
current that was statistically indistinguishable from the initial
response to 5-HT (Initial 5-HT 17.2 	 2.1 pA vs 8-OH-PIPAT
14.9 	 2.7 pA; n  5; not significant; t test paired; t  1.6; Fig.
4C,Ci). As peak response for 8-OH-PIPAT and 8-OH-DPAT of-
ten took time to stabilize and to ensure that it involved opening of
GIRK-like channels, 8-OH-PIPAT was coapplied with Ba2, un-
der which conditions it induced a significantly reduced outward
current compared with initial response to 5-HT (Initial 5-HT
23.7 	 4.6 vs Ba2 PIPAT 2.8 	 0.6 pA; n  9; p  0.005;
ANOVA; F(2,24)  20.2; Fig. 4D,Di). However, subsequent re-
moval of Ba2 revealed the 5-HT1A-mediated outward current,
which proved indistinguishable from the initial response to 5-HT
(20.0	 4.6 pA;n 9; not significant; ANOVA; F(2,24) 20.2; Fig.
4D,Di). Unlike the effects of 5-HT, whichwere readily reversible,
the response of TIDAneurons to 8-OH-PIPAT and 8-OH-DPAT
did not recover in either voltage (n 24 of 24) or current clamp
(n  6 of 6; Fig. 4E), with the 5-HT1A agonists having been
washed from the recording chamber for a minimum of 15 min
(Fig. 4E).
5-HT decreases the frequency of spontaneous and
miniature IPSCs
Having established postsynaptic effects, we investigated whether
5-HT could modulate TIDA spontaneous IPSCs (sIPSCs). Using
highClpipette solution and in the presence ofCNQXandAP-V
to block glutamatergic events, we analyzed and compared sIPSCs
from a 100 s segment before application of 5-HT with sIPSCs
from a 100 s segment during response. Application of 5-HT
induced a reversible increase in sIPSC interevent interval (IEI;
control 460.8 	 94.2 ms, 5-HT 1935.7 	 358.9 ms, washout
604.1 	 111.4 ms; n  11; p  0.005; ANOVA; F(2,30)  25.6;
Fig. 5A–D). To determine the effect of 5-HT on miniature
IPSCs (mIPSCs), TIDA neurons were recorded as above but in
the presence of TTX. Under these conditions, 5-HT did not
affect mIPSC amplitude (control 60.6 	 5.9 pA vs 5-HT
61.2 	 5.4 pA; n  5; not significant; t test paired; t  0.14;
Fig. 6A–D) but did increase IEI (Control 563.5 	 92.6 ms vs
5-HT 1593.3 	 197.3 ms; n  5; p  0.005; t test paired; t 
6.8; Fig. 6A–D). These results suggest that 5-HT reduces
GABA release onto TIDA neurons, without affecting postsyn-
aptic responsiveness to GABA.
Clinically relevant doses of fluoxetine inhibit TIDA neurons’
capacity for repetitive discharge and reduce action potential
(AP) amplitude
Like 5-HT, SSRIs, such as fluoxetine (Prozac; Flx), increase
plasma levels of prolactin in animals (e.g., Morgan and Herbert,
1978) and humans (e.g., Meltzer et al., 1979). Although SSRIs
would, by enhancing ambient 5-HT, modulate TIDA output in-
directly via the 5-HT mechanism described above, we sought to
determine whether SSRIs could further modulate TIDA activity
via a direct, 5-HT-independentmechanism.To this end,we again
used our hypothalamic slice preparation, which, being rapidly
perfused and having neither 5-HT cell bodies nor a means to
stimulate deafferented 5-HT fibers, will have reduced 5-HT re-
uptake for SSRIs to block. As therapeutic concentrations of Flx in
the brain are as high as 30 M (Karson et al., 1993), we tested
TIDA neurons with prolonged (60 min) exposure to Flx at a
concentration of 25 M. In contrast to 5-HT, under this chal-
lenge, TIDAoscillations endured, undergoing only slight changes
in amplitude (Control 29.20 	 2.39 mV vs Flx 60 min 23.84 	
1.74 mV; n  7; p  0.01; t test paired; t  5.9; Fig. 7A,B) and
frequency (Control 0.059	 0.007Hz vs Flx 60min 0.072	 0.005
Hz; n 7; p 0.05; t test paired; t3.3; Fig. 7A,B). Intrinsic
excitability was, however, severely diminished, as assessed by
square-form current injection (20 pA, 500 ms) triggered from a
membrane potential of50 mV. Application of Flx reduced the
depolarization-triggered AP number from 9.2	 1.2 to 1 (n 6;
p 0.005; t test paired; t 7; Fig 7C–E), most prominently after
60 min of drug exposure. AP waveform was also affected, with
amplitude of the initial AP being reduced from 96.3	 2.3 mV in
control to 31.7	 3.8 mV at t 60 min (n 6; p 0.005; t test
paired; t  12.6; Fig. 7C,D). Threshold (Control 39.2 	 0.7
mV; Flx 60min33.2	 1.3mV; n 6; p 0.05; t test paired; t
4.3; Fig. 7C) and half-width (Control 1.5	 0.1 ms; Flx 60 min
4.6 	 0.5ms; n  6; p  0.005; t test paired; t  5.6; Fig. 7C)
were also affected.
With higher doses of Flx (100 M), voltage-clamp recordings
of TIDA neurons revealed a gradual reduction in cycle amplitude
and increase in cycle duration, with the oscillation being com-
pletely abolished after 28.2 	 3.1 min of continuous exposure
(n 10/10; Fig. 8A–D).Despite our recording conditions anduse
of a reduced preparation, there still remained the possibility that,
rather than a 5-HT-independent effect, Flx’s ability to abolish the
TIDA oscillation was the consequence of either, 5-HT accumu-
lation, or the dialysis of intracellular contents associated with
prolonged whole-cell recording. To control for 5-HT accumula-
tion, Flxwas applied in the presence ofNAD299, blocking 5-HT’s
effect at the 1A receptor (identified above as the mediator of
direct electrophysiological actions of 5-HT on TIDA neurons)
and presumably the effect of any increase in ambient 5-HT. These
voltage-clamp recordings showed that prolonged application of
Flx (100 M) still abolished the TIDA oscillation (n  7 of 7;
18.4	 2.4 min; Fig. 9A). In current clamp, Flx at the lower dose
of 25 M, applied in the presence of NAD299, continued to in-
hibit intrinsic excitability, reducing depolarization-induced AP
number from 7.4 	 0.5 to 1.5 	 0.7 (n  8; p  0.005; t test
paired; t  6.6; Fig. 9B). We took a number of different ap-
proaches to control for potential effects of intracellular dialysis.
In the cell-attached recording configuration, thus preserving the
neuron’s internal milieu, Flx (100 M) also abolished TIDA AP
discharge (n 7/7; 15.1	 2.1 min; Fig. 9C). Second, whole-cell
recordings of oscillating TIDA neurons were made after a 30min
incubation with Flx (25 M), and their intrinsic excitability was
compared with TIDA neurons recorded without exposure to Flx.
This challenge also saw a reduction in intrinsic excitability with
depolarization-induced AP discharge decreasing from 7.0 	 0.6
APs in control neurons (n 6) to 1.7	 0.5 APs in Flx-incubated
neurons (n  6; p  0.005; t test unpaired; t  8; Fig. 9D).
Furthermore, when performed in the whole-cell configuration,
prolonged (60 min) control voltage- and current-clamp re-
cordings (i.e., in the absence of any drug application) demon-
strated that TIDA neuronsmaintain their oscillations (n 9 of 9;
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Figure 4. Serotonin inhibits TIDA neurons via activation of the 5-HT 1A receptor. A, Voltage-clamp, oscillating TIDA neuron recorded as in Figure 3A. 5-HT is applied before, during, and after the
5-HT1Aantagonist, NAD299, is present in thebath. Note the complete abolishment of 5-HT response byNAD299. Calibration: 20pA, 60 s.Ai, Box plot organized as Figure 3Bii, illustrating irreversible
I5-HT blockadebyNAD299 (n12).B, Voltage-clamp trace, oscillatingTIDAneuron recordedas in Figure3A. Sequential applicationof 5-HTand the5-HT1Aagonist, 8-OH-DPAT;noteoutward current
induced by both compounds. Calibration: 20 pA, 60 s.Bi, 5-HT and 8-OH-DPAT induce statistically indistinguishable outward currents in TIDA neurons. Box plot organized as Figure 3Bii (n 10). C,
Voltage-clamp trace, oscillating TIDA neuron recorded as in Figure 3A. Sequential application of 5-HT and the 5-HT1A agonist, 8-OH-PIPAT; note outward current induced by both compounds.
Calibration: 20 pA, 60 s.Ci, 5-HT and8-OH-PIPAT induce statistically indistinguishable outward currents in TIDAneurons. Box plot organized as Figure 3Bii (n5).D, Voltage-clamp, oscillating TIDA
neuron recorded as in Figure 3A (note abolishment of oscillation in response to TTX). Following a first exposure to 5-HT, eliciting a reversible outward current, Ba (300M) is bathapplied to the cell.
Note the absence of a response to 8-OH PIPAT (compare C) in the presence of Ba and how, as a consequence of the enduring nature of its interaction with the 5HT-1A receptor, the drug response is fully
uncovered following wash of Ba from the recording chamber. Calibration: 20 pA, 60 s. Di, Ba significantly and reversibly reduces I8-OH-PIPAT. Box plot organized as Figure 3Bii (n 9). E, Current-clamp,
application of 8-OH-PIPAT induces cessation of oscillation andAPdischarge. There is lack of recovery followingwash of 8-OH-PIPAT. Calibration 20mV60 s. ***p 0.005. ns, Not significant.
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Fig. 9E,F) and capacity for repetitive discharge (n  6 of 6; Fig
9F). Collectively, the results from these experiments support the
contention that Flx’s ability to disrupt TIDA neurons’ network
oscillation and discharge pattern is independent of 5-HT’s effects
at the 1A receptor and the cellular dialysis associated with whole-
cell recording.
SSRIs sertraline and fenfluramine also influence TIDA
electrical properties
Hyperprolactinemia has been reported with the clinical use of
other SSRIs, including sertraline (Petit et al., 2003) and fen-
fluramine (Siever et al., 1984). As with Flx, prolonged appli-
cation of sertraline (50 M) induced gradual reductions in AP
Figure 5. Serotonin inhibits sIPSCs in TIDA neurons.A, Voltage-clamp trace showing sIPSCs froman oscillating TIDA neuron, isolated pharmacologically by administration of CNQX and D-AP5 and
recorded with High Cl intracellular solution. Application of 5-HT reversibly induces an outward current and a decrease in sIPSC frequency. Calibration: 50 pA, 60 s. Bi–Biii, Enlarged views of the
100 s sections boxed inAwith corresponding raster plots above. Green represents Control. Red represents 5-HT. Blue representsWash. Calibration: 50pA, 5 s.C, Cumulative probability curves of sIPSC
IEIs generated from the control and 5-HT 100 s sections boxed inA. The distribution shifts to significantly greater IEIs.D, Application of 5-HT significantly and reversibly increases the IEI of sIPSCs. Box
plot organized as Figure 3Bii (n 12). ***p 0.005. ns, Not significant.
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amplitude, capacity for repetitive discharge, and oscillatory activity
(Fig. 10A,B). AP number was reduced from 7.75	 0.75 to 1.75	
0.75 per test pulse (n 4; p 0.05; t test paired; t 8.5; APnumber
fell to 1 in 3 of 4 neurons tested) and amplitude of the initial APwas
reduced from 93.7	 2.1 mV to 41.8	 10.1 mV (n 4; p 0.05; t
test paired; t  4.4). Oscillatory activity was abolished in 4 of 4
neurons after 39.6	 6.1 min (Fig. 10B). Fenfluramine (20 M), in
contrast, abolished oscillation activity more rapidly than the other
Figure 6. Serotonin inhibits mIPSCs in TIDA neurons via a presynaptic mechanism. A, Voltage-clamp trace showing mIPSCs from an oscillating TIDA neuron, isolated as in Fig. 5A, but
with TTX added to abolish AP discharge. Application of 5-HT reversibly induces an outward current and a decrease in mIPSC frequency. Calibration: 40 pA, 20 s. Bi, Bii, Rise alignedmIPSCs
(gray) with averaged event superimposed from boxed areas in A. Green represents Control. Red represents 5-HT. 5-HT application fails to alter meanmIPSC amplitude. Calibration: 30 pA,
10 ms. Biii, Biv, Enlarged views of the 100 s sections boxed in A with corresponding raster plots above. Green represents Control. Red represents 5-HT. Calibration: 40 pA, 5 s. C,
Cumulative probability curves of mIPSCIEIs generated from the control (green) and 5-HT (red) sections boxed in A. The distribution shifts to significantly greater IEIs (K-S2; p 0.001).
D, 5-HT reversibly and significantly increases mIPSC IEI (green), whereas amplitude remains unchanged (red). Thick lines indicate mean	 SEM. Dashed lines indicate raw data (n 5).
ns, Not significant.
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SSRIs tested (11.6 	 2.6 min; n  5; p  0.05; ANOVA; F(2,11) 
11.0; Fig. 10C,D) but following 60 min of exposure did not signifi-
cantly reduce either AP number (5.3	 0.7 in control, 3.3	 1.5 in
fenfluramine; n  3; not significant; t test paired, t  1.3) or the
amplitudeof the initialAP (99.3	3.8mVincontrol, 87.0	7.2mV
in fenfluramine; n 3; not significant; t test paired; t 3).
Discussion
The ability of 5-HT and SSRIs to stimulate prolactin release was
first described40 years ago (Lu andMeites, 1973; Emiliano and
Fudge, 2004). The hyperprolactinemia induced by many SSRIs
has been linked to the sexual side effects associated with these
Figure 7. Clinically relevant concentrations of fluoxetine do not abolish the underlying TIDA oscillation but do inhibit TIDA neurons’ capacity for repetitive discharge and reduce AP
amplitude. A, Current-clamp trace of an oscillating TIDA neuron filtered at 1 Hz in control and following 60 min of 25 M fluoxetine. Calibration 20 mV 20 s. B, Summary of
fluoxetine-induced effects on oscillation amplitude (gray) and frequency (black). Thick lines indicate mean	 SEM. Dashed lines indicate raw data (n 7). C, Peak aligned APs elicited
in response to a square-form–positive current pulse during 60 min application of 25M fluoxetine. There is progressive reduction in AP number and amplitude. Calibration: 16 mV, 4 ms.
Inset, Orbital plots of the first AP highlight change in threshold, amplitude, and rise and decay time. D, Plot showing AP number and amplitude data from the cell depicted in A. E,
Fluoxetine progressively inhibits TIDAneurons’ capacity for repetitive discharge. Thick lines indicatemean	 SEM. Thin lines indicate rawdata (n 6). *p 0.05. **p 0.01. ***p 0.005.
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drugs (Urban and Veldhuis, 1991; Amsterdam et al., 1997; Ekse-
lius et al., 1997), which are common and sufficiently debilitating
to cause drug withdrawal in many patients (Montejo et al., 2001;
van Geffen et al., 2007). Yet, how 5-HT and SSRIs stimulate pro-
lactin release is not well understood. Here we show that 5-HT
activates a K conductance to directly hyperpolarize and inhibit
the firing of rat TIDA neurons in vitro. We further show that
fluoxetine and sertraline also decrease TIDA excitability, but that
the cellular mechanisms, as revealed by recordings in a deaffer-
ented slice preparation lacking serotonergic neurons and in the
continued presence of the 5-HT1A antagonist NAD299, are likely
different from those through which 5-HT acts.
The outward current activated by 5-HT was mimicked by
application of 8-OH-PIPAT and 8-OH-DPAT and was
blocked by prior application of NAD299, indicating that it is
mediated by 5-HT1A receptors. I5-HT displays characteristics of
a GIRK current with its hyperpolarized reversal potential, in-
ward rectification, sensitivity to [Cs]i and [K
]o, and inhi-
bition by Ba2, the GIRK blocker, TQ, and the G-protein
uncoupling agent, NEM. A GIRK-like current modulated by
opioid and GABAB agonists has been described in TIDA neu-
rons (Loose et al., 1990), and GIRK channel subunits are
strongly expressed in the arcuate nucleus (Saenz del Burgo et
al., 2008). Moreover, coupling of the 5-HT1A receptor to GIRK
channels has previously been reported in hippocampal
(Lu¨scher et al., 1997) and raphe (Penington et al., 1993) neu-
rons, and mRNAs encoding these proteins are frequently co-
expressed (Saenz del Burgo et al., 2008).
We thus propose that 5-HT-induced hyperpolarization, un-
derpinned by a 5-HT1A receptor-mediated opening of GIRK-like
channels, abolishes TIDA neuron discharge, which in turn re-
duces dopamine release in the portal capillaries. As such, the
inhibitoryD2R “brake” on lactotrophs is relieved, resulting in the
secretion of prolactin into the general circulation. This scenario is
in agreement with reports that 5-HT agonists, at concentrations
that stimulate prolactin release, decrease the levels of dopamine
in the TIDA-pituitary axis (Pilotte and Porter, 1981) and fail to
increase prolactin when dopamine synthesis has been blocked
(Quattrone et al., 1979). There is also evidence that 5-HT stimu-
lates the release of a prolactin-releasing factor (Clemens et al.,
1978; Pilotte and Porter, 1981), possibilities that are notmutually
exclusive.
Figure 8. Supraclinical concentrations of fluoxetine abolish the TIDA oscillation. A, Voltage-clamp trace of an oscillating TIDA neuron. Application of 100M fluoxetine gradually abolishes TIDA
oscillation. Calibration: 20 pA, 2 min. B, Enlarged color-coded 100 s boxed sections in D filtered at 1 Hz. There is gradual reduction in oscillation amplitude and frequency. Calibration: 10 pA, 5 s.
C, Average oscillation cycle amplitude and duration from the color-coded data depicted inB.D, Spectral density plots of the color-coded data depicted inB. There is successively reduced oscillation
strength and peak frequency.
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The persistence of the 5-HT-induced hyperpolarization in the
presence of TTXand the presence of 5-HT terminals onTIDAcell
bodies (confirming Bosler et al., 1984; Kiss and Hala´sz, 1986)
demonstrates direct, postsynaptic actions of 5-HT on TIDA cells.
We also show, however, a decrease in presynaptic inhibitory in-
puts in response to 5-HT. This finding is perhaps best explained
by anatomical evidence that TIDA neurons are GABAergic
(Everitt et al., 1984) and may auto-innervate (Le´ra´nth et al.,
1985), and also indicates the existence of 5-HT receptors on
the axon terminal as well as the somatodendritic compartment
of TIDA neurons. Thus, the loss of IPSCs may primarily reflect
abolishment of TIDA discharge, further attesting to the pow-
erful inhibition of the system by 5-HT. Modulation of non–
TIDA-derived GABAergic input by 5-HT can, however, not be
excluded.
Fluoxetine and other SSRIs were developed based on the hy-
pothesis that hypoactivity of central serotonergic transmission
underlies depression (see Wong et al., 1995). Given Flx’s proven
ability to increase ambient 5-HT, its prolactin-releasing effects in
the whole animal would then be expected to depend on sero-
tonin’s ability to inhibit TIDA output. Accordingly, in a situation
with little or no 5-HT release or accumulation (such as in our
deafferented, rapidly perfused slice), or in the continued presence
of the 5-HT1A antagonist NAD299, SSRIs would fail to inhibit
TIDA neurons. However, this was clearly not the case, as during
exposure to clinically relevant concentrations (25M) (Karson et
al., 1993) of Flx, the intrinsic excitability of TIDA neurons was
powerfully blunted with decreased AP amplitude and reduced
capacity for repetitive discharge. Notably, however, the oscilla-
tion as such persisted, in sharp contrast to its abolishment in the
presence of 5-HT. At 100M Flx, the oscillation disappeared, but
with a strikingly different temporal profile to 5-HT, a response
preserved despite 5-HT1A receptor blockade. Furthermore,
similar effects were seen with sertraline and fenfluramine.
How can these apparently 5-HT-independent effects be ex-
plained? A solution can be found in the accumulating evidence
for off-target (i.e., nonserotonergic) actions of SSRIs docu-
mented in the literature (see Bianchi, 2008). Studies in other
systems have revealed that Flx can directly modulate particular
membrane currents, including those carried by K (e.g., Tyt-
gat et al., 1997), Ca 2 (e.g., Dea´k et al., 2000), and Cl (e.g.,
Steele et al., 2005). Of particular relevance to the present re-
sults, Flx has been shown to attenuate both persistent (INaP)
and transient sodium currents (INaT), inhibiting repetitive dis-
charge and oscillatory activity in olfactory bulb neurons with a
Figure 9. Fluoxetine’s effects upon TIDA oscillation and repetitive discharge are indepen-
dent of 5-HT1A receptor activation and intracellular dialysis. A, Voltage-clamp trace of an oscil-
lating TIDA neuron filtered at 1 Hz. Application of 100M fluoxetine continues to abolish TIDA
oscillationdespite the continuous presence of the 5-HT1A receptor antagonist, NAD299. Calibra-
tion: 10 pA, 60 s. Inset, Enlarged areas of A denoted by color. Calibration: Inset, 10 pA, 2 s. B,
Fluoxetine continues to inhibit TIDA neuron’s capacity for repetitive discharge, reducing the
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number of APs in response to depolarizing current injection. Box plot organized as Figure 3Bii
(n8). Right, Current-clamp traces showing the voltage response andAPdischarge elicited by
injection of a fixed-amplitude positive current pulse during control (green) and during applica-
tionof fluoxetine (25M). Calibration: 20mV, 50ms.C, Cell-attached recordingof anoscillating
TIDA neuron. Fluoxetine (100M) continues to abolish the TIDA oscillation when intracellular
contents remain undisturbed. Calibration: 10 pA, 2 min. D, Oscillating TIDA neurons patch
clamped in whole-cell configuration following preincubation (30 min) with 25M fluoxetine
(red) also exhibit reduced capacity for repetitive discharge, compared with TIDA neurons that
have not been exposed to fluoxetine (green). Box plot organized as Figure 3Bii (n 6). Right,
Traces organized as in B. Calibration: 20 mV, 50 ms. E, Voltage-clamp trace of oscillating TIDA
neuron. The 60 min of prolonged recording and intracellular dialysis fails to abolish the TIDA
oscillation. Calibration: 20 pA, 2 min. Inset, Expanded areas of E denoted by color, filtered at 1
Hz. Calibration: Inset, 20 pA, 10 s. F, Current-clamp recording of an oscillating TIDA neuron at
t 0 and t 60min. The 60min of prolonged recording fails to abolish TIDAneuron’s capacity
for repetitive discharge. Calibration: 20 mV, 10 s. Inset, Enlarged areas of F overlaid with trace
filtered at 1 HZ according to color. Calibration: Inset, 20 mV, 1 s. ***p 0.005.
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time course very similar to that shown
here (Igelstro¨m and Heyward, 2012). In
TIDA neurons, INaP is an important
contributor to regenerative firing, as ev-
idenced by the abolishment of oscilla-
tory activity by the INaP blocker TTX,
independent of this compound’s effects
on presynaptic input (Lyons et al., 2010;
and unpublished observations). Thus,
the decreased intrinsic excitability ob-
served in TIDA neurons after applica-
tion of Flx and sertraline may be due to
inhibitory actions of these drugs on
INaP. (It may be noted, in this context,
that fenfluramine, which in addition to
suppressing reuptake also stimulates
nonexocytotic release of 5-HT [Kan-
nengiesser et al., 1976], exerted an effect
on a timescale more akin to 5-HT).
Thus, we propose that SSRIs pro-
mote prolactin release in vivo through
two distinct actions on the TIDA net-
work, both resulting in decreased DA
output. First, by increasing 5-HT tone,
SSRIs promote 5-HT1A/GIRK-mediated
hyperpolarization. Second, in a 5-
HT-independent manner, SSRIs reduce
TIDA intrinsic excitability by inhibiting
oscillatory activity and AP discharge, via
reductions in INaT and INaP, respectively.
Combined, these actions would result in
a shutdown of the TIDA system, causing
an increase in prolactin secretion. The
present data thus highlight a novel
mechanism for the hyperprolactinemia
and sexual side effects of SSRIs. It
should be noted that acute drug appli-
cations to slice preparations of TIDA
from the young male rat offers far from
a perfect model of the clinical situation
where SSRIs are prescribed for long pe-
riods to a large and heterogeneous pop-
Figure 10. Sertraline abolishes both the TIDA oscillation and capacity for repetitive discharge, whereas fenlfuramine abolishes
the TIDAoscillationbut leaves the capacity for repetitive discharge intact.A, Current-clamp recordingof anoscillating TIDAneuron.
The response of the cell to injection of square-form–positive current pulses of constant size is tested at regular intervals (e.g., at
asterisks). Prolonged bath application of sertraline results in gradual abolishment of oscillatory activity and reduction
4
in AP amplitude and number, as well as of spontaneous dis-
charge. Calibration: 20 mV, 2 min. Inset, Expanded sections
from A denoted by asterisks. Calibration: Inset, 20 mV, 50 ms.
B, Voltage-clamp recording of a TIDA neuron filtered at 1 Hz.
Prolonged sertraline exposure results in a gradual amplitude
reduction andeventual abolishment of oscillation. Calibration:
20 pA, 4 min. Inset, Expanded areas of B according to color.
Calibration: Inset, 20 pA, 5 s. C, Current-clamp recording of an
oscillating TIDA neuron. The response of the cell to injection of
square-form–positive current pulses of constant size is tested
at regular intervals (e.g., at asterisks). Prolongedbath applica-
tion of fenfluramine results in gradual abolishment of oscilla-
tory activity but fails to reduce capacity for repetitive
discharge. Calibration: 20mV, 2min. Inset, Expanded sections
from C denoted by asterisks. Calibration: Inset, 20 mV, 50 ms.
D, Voltage-clamp recording of a TIDA neuron filtered at 1 Hz.
Prolonged fenfluramine exposure results in a gradual ampli-
tude reduction and eventual abolishment of oscillation. Cali-
bration: 5 pA, 1 min. Inset, Expanded areas of D according to
color. Calibration: Inset, 2 pA, 4 s. **p 0.01.
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ulation for several diagnoses. The ability of these compounds
to elevate circulating prolactin is also less robust when as-
sessed in human subjects than in inbred experimental rodents.
Yet, hyperprolactinemia, as well as adverse reproductive ef-
fects, are notably common when rigorously assessed in SSRI-
treated patients (Montejo-Gonza´lez et al., 1997; Clayton et al.,
2002). Thus, these results may be of importance for the devel-
opment of antidepressant therapies with minimized
reproductive side effects and consequently enhanced patient
compliance.
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